40
Participants
Start Date
April 30, 2016
Primary Completion Date
January 31, 2018
Study Completion Date
January 31, 2018
AK001 low dose
25 mg AK001 will be administered as multiple doses
AK001 high dose
250 mg AK001 will be administered as multiple doses
Placebo
Placebo will be administered as multiple doses
Investigator site, Pittsburgh
Investigator site, Charlottesville
Investigator site, Chicago
Investigator site, Houston
Investigator site, Boston
Investigator site, Ghent
Investigator site, Leuven
Investigator site, Düsseldorf
Investigator site, Münster
Investigator site, Amsterdam
Investigator site, Barcelona
Investigator site, Jerez de la Frontera
Investigator, Valencia
Investigator site, Cambridge
Investigator site, Manchester
Lead Sponsor
Allakos Inc.
INDUSTRY